Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Both this stilbene and quercetin are substrates for the same UDP-glucuronosyltransferase and sulfotransferase isoforms in the gut wall and liver. Co-dosing loads those enzymes and can raise circulating free concentrations of either compound. That is a pharmacokinetic interaction rather than a demonstrated benefit, and it cuts both ways.
This compound is a trihydroxystilbene closely related to resveratrol, differing in the position of the phenolic hydroxyls. It goes through the same rapid glucuronidation and sulfation on first pass, which is why systemic exposure to any of these stilbenes is low relative to the dose taken. Combining them does not solve that problem, it shares it.
When a phenolic compound quenches a radical it becomes a phenoxyl radical itself. Ascorbate reduces that species back to the parent phenol, which is standard antioxidant network chemistry and applies to stilbenes as a class. It describes behaviour in solution, not a measured outcome in a person.
Stilbenes are lipophilic and dissolve poorly in gut fluid, which limits how much can be presented for absorption. Phospholipid complexes and lecithin dispersions raise apparent solubility and are a standard formulation answer for this class. The gain is in dissolution, and dissolution is only one of the barriers.
Piperine inhibits intestinal UGT activity, and glucuronidation is the main reason stilbene blood levels stay low after an oral dose. Pairing the two raises systemic exposure of the parent compound. The same inhibition applies to co-administered drugs, which is why the pairing is not a free lunch.
Taking a lipophilic polyphenol with a fat source stimulates bile release and micelle formation, which puts more of the compound into an absorbable state. Fasted dosing of a dry stilbene powder is the worst case for uptake. This is general lipophilic-nutrient handling applied to the class.
Stilbenes often arrive in plant material as glycosides, and gut bacterial glycosidases cleave the sugar to release the free aglycone that can cross the enterocyte. Which bacteria are present therefore shapes how much free compound is generated. Individual conversion capacity varies widely and is not routinely measured.
Nothing specific on file for 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.